COMMUNIQUÉS West-GlobeNewswire
-
Shoreline Recovery Center Experts Announce New Therapeutic Approach In Addiction Recovery
10/03/2026 -
NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer’s Disease at AD/PD™ 2026
10/03/2026 -
Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit
10/03/2026 -
Femasys Advances FemBloc Toward U.S. Approval with Initiation of Pivotal Trial Enrollment
10/03/2026 -
API Innovation Center Highlights Fragility in U.S. Drug Supply Chain in New White Paper
10/03/2026 -
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026 -
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting
10/03/2026 -
UPDATED – Moving from Pledge to Production, Clover Health is Now Live on Kno2, Participating in Recently Announced Federal Interoperability Initiatives
10/03/2026 -
VIVUS Announces QSIVA® Price Reduction Across Nordics and Poland
10/03/2026 -
Celularity Secures $35 Million Strategic License Deal, Strengthens Capital Position to Advance Longevity-Focused Strategy
10/03/2026 -
HealthEdge HealthRules® Payer Works with AWS to Set a New Scalability Benchmark, Expanding to Support Health Plans with More Than 40 Million Members
10/03/2026 -
GLP Diet Review: A Personalized App Designed to Support GLP-1 Weight Loss Journeys
10/03/2026 -
Spectral AI Schedules 2025 Fourth Quarter and Full Year Financial Results and Conference Call
10/03/2026 -
Natural Remedies Advances Sleep Health Research with Holixer During National Sleep Awareness Month
10/03/2026 -
Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study
10/03/2026 -
Microbot Medical® to Participate at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference for The First Time
10/03/2026 -
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
10/03/2026 -
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
10/03/2026 -
SS Innovations Reports Fourth Quarter and Full Year 2025 Financial Results
10/03/2026
Pages